Molecular Diagnosis & Therapy, published by ADIS INT LTD, is a premier journal dedicated to the cutting-edge fields of genetics, molecular medicine, and pharmacology. With a strong emphasis on the translation of molecular insights into innovative therapeutic strategies, this journal serves as a vital resource for researchers, clinicians, and students aiming to stay at the forefront of medical and scientific advancements. The journal boasts an impressive standing in its categories, holding a Q1 ranking in Genetics, Medicine (miscellaneous), and Pharmacology, alongside a Q2 classification in Molecular Medicine for 2023, reflecting its influential contributions to the scientific community. Indexed in Scopus, it occupies distinct positions in its respective fields, ranked #77 in Genetics and Pharmacology, and #53 in Molecular Medicine, highlighting its robust impact factor and scholarly influence. Although it is not open access, the journal ensures widespread dissemination of valuable research, promoting enhanced understanding of molecular diagnostic techniques and therapeutic interventions. Since its inception in 2001, and continuing through to 2024, Molecular Diagnosis & Therapy remains an essential platform for disseminating vital research findings, fostering academic collaboration, and driving forward the dialogue in molecular diagnostics and treatment methodologies.

Indonesian Biomedical Journal, published by PRODIA EDUCATION & RESEARCH INST, serves as a vital platform for the dissemination of groundbreaking research in the fields of biochemistry, genetics, and molecular biology, as well as general medicine. Since its inception, this Open Access journal has made significant strides in enhancing accessibility to scientific knowledge, allowing researchers, professionals, and students to engage with high-quality studies without financial barriers. With an ISSN of 2355-9179 and a focus on emerging biomedical topics, the journal has established itself in the academic community, securing Q3 and Q4 rankings in its respective categories for 2023. The journal's commitment to maintaining a rigorous peer-review process ensures that only the most innovative and impactful research is published, fostering an environment that encourages collaborative learning and discovery. As it converges from 2017 to 2024, the Indonesian Biomedical Journal continues to be an essential resource for those involved in advancing biomedical sciences, particularly within the unique context of Indonesia and beyond.

Molecular Biology Research Communications is a distinguished academic journal published by Shiraz University, focusing on the critical and rapidly evolving fields of biochemistry and molecular biology. With an ISSN of 2322-181X and an E-ISSN of 2345-2005, this journal serves as an essential platform for researchers, professionals, and students to disseminate significant findings that contribute to the advancement of knowledge in these disciplines. The journal, operating from Shiraz, Iran, is notable for its contributions from both local and international scholars, offering invaluable insights and fostering scientific collaboration. Although currently indexed in the Q4 quartile across its categories, the journal aims to enhance its impact and visibility in the field as it converges years of research from 2017 to 2024. While the open access option is not available, the journal's commitment to high-quality peer-reviewed research provides a respected avenue for publication.

ACTA HISTOCHEMICA, a prestigious journal published by Elsevier GmbH, is dedicated to advancing the field of histochemistry and its applications within cell biology and medicine. With an ISSN of 0065-1281 and an E-ISSN of 1618-0372, the journal provides a critical platform for the dissemination of high-quality research findings and reviews, integral for both emerging and established scholars. Since its inception in 1954 and continuing through to 2024, ACTA HISTOCHEMICA has maintained a strong commitment to publishing significant advancements in histology and cell biology, as evidenced by its categorization in Q3 for Cell Biology and Histology, as well as Q2 in miscellaneous medicine for the year 2023. The journal ranks favorably in Scopus, holding the 27th rank in Histology and a 200th rank in Cell Biology, highlighting its importance to the academic community. With its headquarters in Munich, Germany, ACTA HISTOCHEMICA continues to attract contributions from global researchers, fostering an international dialogue essential for the growth of knowledge in histochemistry and related disciplines.

HISTOCHEMISTRY AND CELL BIOLOGY, published by SPRINGER, is a prominent journal dedicated to advancing the fields of histochemistry and cell biology. With an ISSN of 0948-6143 and an E-ISSN of 1432-119X, this journal has carved a significant niche since its inception in 1995, striving for excellence in research dissemination through a rigorous peer-review process. The journal's impact is reflected in its strong performance across various academic categories, achieving a Q1 ranking in Medical Laboratory Technology, Q2 in Histology, and maintaining a credible presence in Cell and Molecular Biology. Nestled in Germany, and with the backing of a reputable publisher, HISTOCHEMISTRY AND CELL BIOLOGY serves as a pivotal platform for researchers, professionals, and students, fostering innovations that push the boundaries of our understanding of cellular processes. While the journal is not open access, it offers subscription-based access options ensuring comprehensive coverage of crucial findings in the rapidly evolving arena of cell biology and histochemistry.

Biomarker Insights, published by SAGE Publications Ltd, is a leading open-access journal dedicated to advancing the field of biomarker research and its applications in health and disease. With an ISSN of 1177-2719 and an E-ISSN of 1177-2719, this journal has been at the forefront of disseminating high-quality scientific findings since its inception in 2006. Based in New Zealand, it has achieved a notable impact within the academic community, ranking in Q2 for Biochemistry (medical) and Molecular Medicine, and Q1 in Pharmacology as of 2023. This positions Biomarker Insights as a critical resource for researchers, professionals, and students alike, looking to explore innovative methodologies and applications in biomarker discovery and validation. With a commitment to open access, the journal ensures that groundbreaking research is readily available to the global community, fostering collaboration and innovation in the ever-evolving field of biomedical sciences.

BIOMEDICAL RESEARCH-TOKYO is an esteemed interdisciplinary journal published by BIOMEDICAL RESEARCH PRESS LTD, dedicated to disseminating pioneering research and advancements in the fields of biochemistry, genetics, and medicine. Since its inception in 1980, the journal has established itself as a reputable source of knowledge, contributing significantly to the global scientific community with its strong emphasis on innovative findings and methodologies. With a consistent presence in the Q3 quartile for both Biochemistry, Genetics and Molecular Biology and Medicine categories as of 2023, it continues to attract a diverse range of research articles. While the journal does not operate as an open access platform, it remains an essential resource for researchers, professionals, and students seeking to further their understanding of biomedical sciences. Located in Sapporo, Japan, this journal fosters collaboration and knowledge sharing among the international biomedical research community, engaging readers through its compelling studies that span from 1980 to 2024.

TECHNOLOGY IN CANCER RESEARCH & TREATMENT, published by SAGE Publications Inc, is a leading open-access journal dedicated to the intersection of technology and oncology. Since its inception in 2002 and with an impactful transition to open access in 2018, it has garnered attention for its commitment to disseminating groundbreaking research that explores innovative methodologies and technologies in cancer diagnostics and therapeutics. With ISSN 1533-0346 and E-ISSN 1533-0338, the journal is highly relevant in the fields of Cancer Research (Q3), Medicine (Q2), and Oncology (Q3), as indicated by its 2023 category quartiles. Its Scopus rankings further highlight its position within the research community, standing at #186 out of 404 in Medicine and #141 out of 230 in Cancer Research. Through a carefully curated selection of articles, this journal aims to bridge the gap between technological advancement and clinical application, providing a vital resource for researchers, healthcare professionals, and students striving to improve cancer treatment outcomes.

Minerva Biotechnology and Biomolecular Research is an emerging journal published by EDIZIONI MINERVA MEDICA, dedicated to the fields of biotechnology, biomolecular research, and applied microbiology. With an ISSN of 2724-542X and an E-ISSN of 2724-5934, this journal aims to foster deeper understanding and innovative advancements in these rapidly evolving disciplines. The journal has been categorized in the Q4 quartile across four categories in the 2023 rankings, highlighting its nascent yet growing influence within the scientific community. Operating on an open-access model, it enhances accessibility and encourages the dissemination of knowledge to researchers, professionals, and students alike. Set in the heart of Italy, specifically at CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY, Minerva Biotechnology and Biomolecular Research will continue to enrich the scientific literature from its inception in 2021 through 2024 and beyond, contributing to the global dialogue on biotechnological innovations and molecular research.

Revista Romana de Medicina de Laborator is a prominent open-access journal published by SCIENDO, dedicated to the field of medical laboratory technology and biochemistry. Since its inception, this journal has been a vital platform for disseminating research findings and advancements in laboratory medicine. With an ISSN of 1841-6624 and E-ISSN 2284-5623, it has served the academic community since 2008 and has embraced an open-access model since 2013, ensuring that valuable research is accessible to all. While it features niche rankings in Scopus for areas such as Medical Laboratory Technology and Clinical Biochemistry, it consistently strives to engage researchers, professionals, and students. Its rich collection of articles highlights innovative techniques and methodologies, supporting the ongoing development of laboratory practices. Although its coverage in Scopus has been discontinued, the journal continues to publish high-quality studies that contribute significantly to the field, fostering knowledge exchange essential for advancing medical science.